vs
STANDARD BIOTOOLS INC.（LAB）与La Rosa Holdings Corp.（LRHC）财务数据对比。点击上方公司名可切换其他公司
La Rosa Holdings Corp.的季度营收约是STANDARD BIOTOOLS INC.的1.0倍（$20.2M vs $19.6M），La Rosa Holdings Corp.净利率更高（-27.4% vs -177.4%，领先150.0%），La Rosa Holdings Corp.同比增速更快（3.2% vs -11.5%），过去两年La Rosa Holdings Corp.的营收复合增速更高（72.5% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
拉罗萨控股旗下的万拉罗萨父子通心粉公司由西西里移民文森佐·拉罗萨于1914年创立，发展至今已成为美国规模领先的区域知名食品品牌，可生产四十余种意面产品，在当地市场拥有较高的认可度。
LAB vs LRHC — 直观对比
营收规模更大
LRHC
是对方的1.0倍
$19.6M
营收增速更快
LRHC
高出14.7%
-11.5%
净利率更高
LRHC
高出150.0%
-177.4%
两年增速更快
LRHC
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $20.2M |
| 净利润 | $-34.7M | $-5.5M |
| 毛利率 | 48.5% | 8.4% |
| 营业利润率 | -168.5% | -24.7% |
| 净利率 | -177.4% | -27.4% |
| 营收同比 | -11.5% | 3.2% |
| 净利润同比 | -28.8% | -125.7% |
| 每股收益（稀释后） | $-0.09 | $-5.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABLRHC
| Q3 25 | $19.6M | $20.2M | ||
| Q2 25 | $21.8M | $23.2M | ||
| Q1 25 | $40.8M | $17.5M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | $22.1M | $19.6M | ||
| Q2 24 | $22.5M | $19.1M | ||
| Q1 24 | $45.5M | $13.1M | ||
| Q4 23 | $28.2M | — |
净利润LABLRHC
| Q3 25 | $-34.7M | $-5.5M | ||
| Q2 25 | $-33.5M | $78.4M | ||
| Q1 25 | $-26.0M | $-95.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | $-26.9M | $-2.5M | ||
| Q2 24 | $-45.7M | $-2.3M | ||
| Q1 24 | $-32.2M | $-4.6M | ||
| Q4 23 | $-19.8M | — |
毛利率LABLRHC
| Q3 25 | 48.5% | 8.4% | ||
| Q2 25 | 48.8% | 8.0% | ||
| Q1 25 | 48.4% | 8.8% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | 54.9% | 8.3% | ||
| Q2 24 | 46.1% | 8.3% | ||
| Q1 24 | 53.1% | 8.9% | ||
| Q4 23 | 47.6% | — |
营业利润率LABLRHC
| Q3 25 | -168.5% | -24.7% | ||
| Q2 25 | -118.1% | -10.6% | ||
| Q1 25 | -80.8% | -26.7% | ||
| Q4 24 | — | -17.1% | ||
| Q3 24 | -120.9% | -8.9% | ||
| Q2 24 | -134.5% | -9.7% | ||
| Q1 24 | -132.2% | -35.0% | ||
| Q4 23 | -75.9% | — |
净利率LABLRHC
| Q3 25 | -177.4% | -27.4% | ||
| Q2 25 | -153.7% | 337.8% | ||
| Q1 25 | -63.8% | -546.5% | ||
| Q4 24 | — | -28.7% | ||
| Q3 24 | -122.0% | -12.5% | ||
| Q2 24 | -203.3% | -12.2% | ||
| Q1 24 | -70.6% | -35.1% | ||
| Q4 23 | -70.2% | — |
每股收益（稀释后）LABLRHC
| Q3 25 | $-0.09 | $-5.44 | ||
| Q2 25 | $-0.09 | $15.25 | ||
| Q1 25 | $-0.07 | $-5.86 | ||
| Q4 24 | — | $28.54 | ||
| Q3 24 | $-0.07 | $-16.49 | ||
| Q2 24 | $-0.12 | $-12.49 | ||
| Q1 24 | $-0.27 | $-0.35 | ||
| Q4 23 | $-0.24 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $4.0M |
| 总债务越低越好 | — | $642.8K |
| 股东权益账面价值 | $399.7M | $1.6M |
| 总资产 | $539.6M | $21.7M |
| 负债/权益比越低杠杆越低 | — | 0.41× |
8季度趋势，按日历期对齐
现金及短期投资LABLRHC
| Q3 25 | $129.4M | $4.0M | ||
| Q2 25 | $158.6M | $5.1M | ||
| Q1 25 | $150.9M | $2.9M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $210.6M | $1.8M | ||
| Q2 24 | $269.8M | $1.6M | ||
| Q1 24 | $287.1M | $1.1M | ||
| Q4 23 | $51.7M | — |
总债务LABLRHC
| Q3 25 | — | $642.8K | ||
| Q2 25 | — | $644.3K | ||
| Q1 25 | — | $645.9K | ||
| Q4 24 | — | $647.6K | ||
| Q3 24 | $55.2M | $649.2K | ||
| Q2 24 | $55.1M | $650.8K | ||
| Q1 24 | $55.0M | $652.4K | ||
| Q4 23 | $63.5M | — |
股东权益LABLRHC
| Q3 25 | $399.7M | $1.6M | ||
| Q2 25 | $424.5M | $3.4M | ||
| Q1 25 | $454.6M | $-87.5M | ||
| Q4 24 | — | $2.6M | ||
| Q3 24 | $489.3M | $5.0M | ||
| Q2 24 | $510.3M | $4.7M | ||
| Q1 24 | $577.3M | $5.6M | ||
| Q4 23 | $-148.1M | — |
总资产LABLRHC
| Q3 25 | $539.6M | $21.7M | ||
| Q2 25 | $557.0M | $22.9M | ||
| Q1 25 | $579.6M | $21.0M | ||
| Q4 24 | — | $19.4M | ||
| Q3 24 | $681.5M | $19.7M | ||
| Q2 24 | $708.7M | $18.7M | ||
| Q1 24 | $777.7M | $16.3M | ||
| Q4 23 | $323.1M | — |
负债/权益比LABLRHC
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | 0.11× | 0.13× | ||
| Q2 24 | 0.11× | 0.14× | ||
| Q1 24 | 0.10× | 0.12× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-1.3M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABLRHC
| Q3 25 | $-22.2M | $-1.3M | ||
| Q2 25 | $-20.7M | $-1.4M | ||
| Q1 25 | $-30.3M | $-3.5M | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | $-27.9M | $-591.6K | ||
| Q2 24 | $-39.0M | $-803.1K | ||
| Q1 24 | $-62.5M | $-538.3K | ||
| Q4 23 | $-14.1M | — |
自由现金流LABLRHC
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — |
自由现金流率LABLRHC
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — |
资本支出强度LABLRHC
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — |
现金转化率LABLRHC
| Q3 25 | — | — | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
